Buscar
Mostrando ítems 1-10 de 284
Transforming vaccine development
The urgency to develop vaccines against Covid-19 is putting pressure on the long and expensive development
timelines that are normally required for development of lifesaving vaccines. There is a unique opportunity to ...
A short hairpin RNA-based adjuvant targeting NF-κB repressor IκBα promotes migration of dermal dendritic cells to draining lymph nodes and antitumor CTL responses induced by DNA vaccination
(Elsevier Ltd, 2017)
© 2017 Elsevier Ltd DNA vaccination is an attractive approach to elicit tumor-specific cytotoxic CD8+ T lymphocytes (CTL), which can mediate protective immunity against tumors. To initiate CTL responses, antigen-encoding ...
Genetic engineering of Lactococcus lactis co-producing antigen and the mucosal adjuvant 3' 5'- cyclic di Adenosine Monophosphate (c-di-AMP) as a design strategy to develop a mucosal vaccine prototype
(Frontiers Research Foundation, 2018-09)
Lactococcus lactis is a promising candidate for the development of mucosal vaccines. More than 20 years of experimental research supports this immunization approach. In addition, 3' 5'- cyclic di-adenosine monophosphate ...
Role of interferon-gamma during CpG oligodeoxynucleotide-adjuvanted immunization with recombinant proteins
(Elsevier B.V., 2007-08-10)
Synthetic oligonucleotides (ODNs) containing immunostimulatory CpG motifs (CpG) are a new class of adjuvants suitable for the development of recombinant vaccines. Here we describe that endogenous interferon (IFN) was ...
Protective immunity to DENV2 after immunization with a recombinant NS1 protein using a genetically detoxified heat-labile toxin as an adjuvant
(ELSEVIER SCI LTDOXFORD, 2012)
The dengue virus non-structural 1 (NS1) protein contributes to evasion of host immune defenses and represents a target for immune responses. Evidences generated in experimental models, as well as the immune responses ...